Want to see ALMS full AI Analyst Report?
Alumis Inc. (ALMS) AI Stock Analysis
Top Page
Alumis Inc.
(NASDAQ:ALMS)
The score is held down primarily by weak financial performance (large operating losses and very heavy negative free cash flow) and bearish technical momentum (price below major moving averages with negative MACD and very low RSI/Stoch). Mixed clinical trial news provides some support, but it does not offset the near-term profitability and funding risks reflected in the financials.
Alumis Inc. (ALMS) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $871.10M
- Dividend Yield
- ―
- Average Volume (3M)
- 2.66M
- Price to Earnings (P/E)
- -1.8
- Beta (1Y)
- -1.34
- Revenue Growth
- -63.11%
- EPS Growth
- 15.36%
- Country
- US
- Employees
- 237
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Alumis Inc. Business Overview & Revenue Model
Company Description
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psori...
Alumis Inc. Financial Statement Overview
Summary
Financials are dominated by heavy losses and cash burn: TTM revenue is modest ($7.4M) and declining (~12%), operating/net margins are deeply negative (~-60%), and operating/free cash flow are extremely negative (about -$351M/-$352M). The balance sheet is a relative bright spot with low leverage (debt-to-equity ~0.08) and improved capitalization, but profitability and funding runway risk remain central.
Income Statement
18Very NegativeBalance Sheet
64PositiveCash Flow
12Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.40M | 24.05M | 0 | 0 | 0 |
| Gross Profit | 6.53M | 20.55M | -3.15M | 0 | -250.00K |
| EBITDA | -441.99M | -248.39M | -291.08M | -153.71M | -111.68M |
| Net Income | -438.96M | -243.32M | -294.23M | -154.99M | -111.93M |
Balance Sheet | |||||
| Total Assets | 560.62M | 411.94M | 340.99M | 89.61M | 108.17M |
| Cash, Cash Equivalents and Short-Term Investments | 502.29M | 308.50M | 288.26M | 48.95M | 92.86M |
| Total Debt | 36.43M | 36.91M | 30.72M | 32.58M | 1.78M |
| Total Liabilities | 108.46M | 110.64M | 80.89M | 428.87M | 303.41M |
| Stockholders Equity | 452.16M | 301.30M | 260.10M | -339.26M | -195.24M |
Cash Flow | |||||
| Free Cash Flow | -351.80M | -370.18M | -256.81M | -134.47M | -110.13M |
| Operating Cash Flow | -351.40M | -369.52M | -255.08M | -129.97M | -107.72M |
| Investing Cash Flow | -97.94M | 287.88M | -113.79M | 60.47M | -68.75M |
| Financing Cash Flow | 360.93M | 2.07M | 492.37M | 89.68M | 101.63M |
Alumis Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALMS, the sentiment is Negative. The current price of 6.73 is above the 20-day moving average (MA) of 6.71, below the 50-day MA of 9.86, and below the 200-day MA of 21.42, indicating a neutral trend. The MACD of -0.82 indicates Negative momentum. The RSI at 37.34 is Neutral, neither overbought nor oversold. The STOCH value of 70.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALMS.
Alumis Inc. Risk Analysis
Alumis Inc. disclosed 78 risk factors in its most recent earnings report. Alumis Inc. reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksAlumis Inc. Peers Comparison
Overall Rating
QTTB57Neutral
ZURA47Neutral- ALMS43Neutral
ACRS42Neutral
AVTX40Underperform
MLTX39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| QTTB | 57Neutral | $265.25M | 3.19 | 76.88% | ― | ― | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| ZURA | 47Neutral | $389.15M | -3.61 | -53.97% | ― | ― | -76.37% |
| ALMS | 43Neutral | $898.42M | -1.77 | -102.97% | ― | -63.11% | 15.36% |
| ACRS | 42Neutral | $584.38M | -6.84 | -61.65% | ― | -51.05% | 57.25% |
| AVTX | 40Underperform | $384.53M | -1.51 | -58.03% | ― | -86.62% | 14.74% |
| MLTX | 39Underperform | $1.00B | -3.06 | -82.68% | ― | ― | -37.48% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ALMS | Alumis Inc. | 6.73 | 2.17 | 47.59% | |
| ACRS | Aclaris Therapeutics Inc. | 3.97 | 1.41 | 55.08% | |
| AVTX | Avalo Therapeutics, Inc. | 7.17 | -9.50 | -56.99% | |
| QTTB | Q32 Bio Inc | 8.91 | 6.34 | 246.69% | |
| MLTX | Moonlake Immunotherapeutics | 11.78 | 1.58 | 15.49% | |
| ZURA | Zura Bio Limited | 4.04 | 0.36 | 9.78% |
Alumis Inc. Corporate Events
Alumis Reports Phase 2b Envudeucitinib Data in Lupus
NegativeOn September 1, 2026, Alumis reported topline data from its Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus, noting that the study failed to meet its primary and secondary endpoints in the overall population...
Alumis reports strong Phase 3 data for envudeucitinib
PositiveOn August 10, 2026, Alumis reported topline long-term extension data from its Phase 3 ONWARD3 study of envudeucitinib in moderate-to-severe plaque psoriasis. The investigational oral TYK2 inhibitor delivered leading skin clearance, with 75% of patien...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 15, 2026